

Clinical trials of saruplase

TrialResults-center www.trialresultscenter.org

1 acute myocardial infarction

Trial	Treatments	Patients	Trials design and methods
saruplase vs streptokinase			
COMPASS , 1998 n=1542/1547 follow-up: 1 y	saruplase 20-mg bolus and 60-mg infusion over 60 min versus streptokinase 1.5-MU infusion over 60 min	patients with symptoms compatible with those of acute myocardial infarction for <6 h	Parallel groups double blind
PRIMI (vs SK) , 1989 n=198/203 follow-up: ND	saruplase 20 mg bolus followed by 60 mg infusion for 60 min versus 1.5 million IU streptokinase infused over 60 min	patients with acute myocardial infarction were within 4 h of onset of symptoms	Parallel groups double blind
saruplase vs t-PA			
SESAM , 1997 n=236/237 follow-up: hospital stay	saruplase 80 mg/hour versus alteplase 100 mg every 3 hours	patients with acute myocardial infarction	Parallel groups open Europe
saruplase vs urokinase			
PRIMI (vs UK) , 1989 n=198 follow-up:	20 mg bolus followed by 60 mg infusion for 60 min versus 80 mg recombinant pro-urokinase	with a first acute myocardial infarction within 4 h of onset of symptoms	Parallel groups double blind

More details and results :

- myocardial revascularization for acute myocardial infarction in all type of patients at <http://www.trialresultscenter.org/go-Q129>
- fibrinolysis for acute myocardial infarction in all type of patients at <http://www.trialresultscenter.org/go-Q260>

References

COMPASS, 1998:

Tebbe U, Michels R, Adgey J, Boland J, Caspi A, Charbonnier B, Windeler J, Barth H, Groves R, Hopkins GR, Fennell W, Betriu A, Ruda M, Mlczech J Randomized, double-blind study comparing saruplase with streptokinase therapy in acute myocardial infarction: the COMPASS Equivalence Trial. Comparison Trial of Saruplase and Streptokinase (COMASS) Investigators J Am Coll Cardiol 1998;31:487-93 [[9502624](https://pubmed.ncbi.nlm.nih.gov/9502624/)]

PRIMI (vs SK), 1989:

Randomised double-blind trial of recombinant pro-urokinase against streptokinase in acute myocardial infarction. PRIMI Trial Study Group Lancet 1989;1:863-8 [2564949]

SESAM, 1997:

Br FW, Meyer J, Vermeer F, Michels R, Charbonnier B, Haerten K, Spiecker M, Macaya C, Hanssen M, Heras M, Boland JP, Morice MC, Dunn FG, Uebis R, Hamm C, Ayzenberg O, Strupp G, Withagen AJ, Klein W, Windeler J, Hopkins G, Barth H, von Fisenne MJ Comparison of saruplase and alteplase in acute myocardial infarction. SESAM Study Group. The Study in Europe with Saruplase and Alteplase in Myocardial Infarction. Am J Cardiol 1997 Mar 15;79:727-32 [9070549]

PRIMI (vs UK), 1989:

Randomised double-blind trial of recombinant pro-urokinase against streptokinase in acute myocardial infarction. PRIMI Trial Study Group. Lancet 1989 Apr 22;1:863-8 [2564949]

Entry terms: saruplase, prourokinase (enzyme-activating), recombinant unglycosylated single-chain urokinase-type plasminogen activator, pro-urokinase, Rescupase, A-74187,